MiR-155 and miR-484 are associated with time to progression in metastatic renal cell carcinoma treated with sunitinib

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Merhautova, Jana ^a   Hezova, Renata ^a,b   Poprach, Alexandr ^b   Kovarikova, Alena ^a   Radova, Lenka ^a   Svoboda, Marek ^a,b   Vyzula, Rostislav ^b   Demlova, Regina ^a   Slaby, Ondrej ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 155; MICRORNA 302C; MICRORNA 374 5P; MICRORNA 484; MICRORNA 888; SUNITINIB; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; MIRN155 MICRORNA, HUMAN; MIRN484 MICRORNA, HUMAN; PYRROLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE LEVEL; TREATMENT RESPONSE; BIOSYNTHESIS; CARCINOMA, RENAL CELL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES;

EID: 84929650622     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/941980     Document Type: Article

References (18)

1. B. I. Rini and M. B. Atkins, "Resistance to targeted therapy in renal-cell carcinoma, " The Lancet Oncology, vol. 10, no. 10, pp. 992-1000, 2009.
2. A. Bex, B. K. Kroon, and R. de Bruijn, "Is there a role for neoadjuvant targeted therapy to downsize primary tumors for organ sparing strategies in renal cell carcinoma?" International Journal of Surgical Oncology, vol. 2012, Article ID 250479, 6 pages, 2012.
3. H. Mlcochova, R. Hezova, M. Stanik, and O. Slaby, "Urine microRNAs as potential noninvasive biomarkers in urologic cancers, " Urologic Oncology: Seminars and Original Investigations, vol. 32, no. 1, pp. 41. e1-41. e9, 2014.
4. C. Wang, J. Hu, M. Lu et al. , "A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma, " Scientific Reports, vol. 5, article 7610, 2015.
5. P. J. Mishra, "MicroRNAs as promising biomarkers in cancer diagnostics, " Biomarker Research, vol. 2, no. 19, 2014.
6. T. F. Hansen, A. L. Carlsen, N. H. Heegaard, F. B. Sørensen, andA. Jakobsen, "Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer, " British Journal of Cancer, vol. 112, no. 4, pp. 624-629, 2015.
7. N. M. A. White, T. T. Bao, J. Grigull et al. , "MiRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation, " The Journal of Urology, vol. 186, no. 3, pp. 1077-1083, 2011.
8. S. Li, T. Chen, Z. Zhong, Y. Wang, Y. Li, and X. Zhao, "Micro-RNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells, " Molecular Medicine Reports, vol. 5, no. 4, pp. 949-954, 2012.
9. A. Wojcicka, A. Piekielko-Witkowska, H. Kedzierska et al. , "Epigenetic regulation of thyroid hormone receptor beta in renal cancer, " PLoS ONE, vol. 9, no. 5, Article ID e97624, 2014.
10. S. Biswas, H. Troy, R. Leek et al. , "Effects of HIF-1 and HIF2 on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts, " Journal of Oncology, vol. 2010, Article ID 757908, 14 pages, 2010.
11. W. Kong, L. He, E. J. Richards et al. , "Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer, " Oncogene, vol. 33, no. 6, pp. 679-689, 2014.
12. C. Prior, J. L. Perez-Gracia, J. Garcia-Donas et al. , "Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma, " PLoS ONE, vol. 9, no. 1, Article ID e86263, 2014.
13. A. Vecchione, B. Belletti, F. Lovat et al. , "A microRNA signature defines chemoresistance in ovarian cancer throughmodulation of angiogenesis, " Proceedings of theNationalAcademy of Sciences of the United States of America, vol. 110, no. 24, pp. 9845-9850, 2013.
14. A. Li, J. Yu, H. Kim et al. , "MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls, " Clinical Cancer Research, vol. 19, no. 13, pp. 3600-3610, 2013.
15. S. Zearo, E. Kim, Y. Zhu et al. , "MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers, " BMC Cancer, vol. 14, no. 1, article 200, 2014.
16. J. B. Kjersem, T. Ikdahl, O. C. Lingjaerde, T. Guren, K. M. Tveit, and E. H. Kure, "Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment, " Molecular Oncology, vol. 8, no. 1, pp. 59-67, 2014.
17. E. I. Bimpaki, D. Iliopoulos, A. Moraitis, and C. A. Stratakis, "MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis, " Clinical Endocrinology, vol. 72, no. 6, pp. 744-751, 2010.
18. K. Wang, B. Long, J.-Q. Jiao et al. , "MiR-484 regulates mitochondrial network through targeting Fis1, " Nature Communications, vol. 3, article 781, 2012.